Showing results (371-380 of 4,241) with videos related to
Sort By:
Pageof 425
Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.Journal for Immunotherapy of Cancer|December 21, 2025
TIPE2 deficiency enhances macrophage phagocytosis of tumor cellsZelong Ma, Yingyue Wang, Yanlei Dong, et al.Journal for Immunotherapy of Cancer|December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancerXinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.Journal for Immunotherapy of Cancer|January 13, 2026
Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockadeJürgen C Becker, Georg Lodde, Maximilian Haist, et al.Journal for Immunotherapy of Cancer|January 13, 2026
Decoding adipocyte heterogeneity through single-nucleus transcriptomics unveils subtype-specific adipocytes orchestrate immunosuppressive niches in breast cancerYiwei Tong, Zheng Wang, Niu Qiao, et al.Journal for Immunotherapy of Cancer|December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.Journal for Immunotherapy of Cancer|April 29, 2025
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapyAndrew A Almonte, Laurence ZitvogelJournal for Immunotherapy of Cancer|April 30, 2025
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progressionJavier Arroyo-Ródenas, Aida Falgas, Laura Díez-Alonso, et al.Journal for Immunotherapy of Cancer|April 12, 2025
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancerYing Jiang, Zhiwen Qian, Cenzhu Wang, et al.Journal for Immunotherapy of Cancer|April 11, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effectsMichela Capello, Angelica Sette, Theo Plantinga, et al.Pageof 425